Managing transplant ineligible AML patients
How is the landscape of Hodgkin lymphoma therapy changing?
Re-analysis of RESONATE-2 trial of ibrutinib vs chlorambucil in CLL
Multiple myeloma highlights from ASCO 2016: monoclonal antibodies and oral proteasome inhibitors
The 2016 International Workshop of the German CLL Study Group (GCLLSG)